US00688A2050 - Common Stock
ADIAL PHARMACEUTICALS INC
NASDAQ:ADIL (5/3/2024, 7:00:00 PM)
After market: 1.7 0 (0%)1.7
-0.09 (-5.03%)
Adial Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Charlottesville, Virginia and currently employs 16 full-time employees. The company went IPO on 2018-07-27. Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. The Company’s drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder (AUD). AD04 is used for the treatment of AUD in subjects with certain target genotypes, which were identified using its companion diagnostic genetic test. AD04 is a genetically targeted, serotonin-3 receptor antagonist, a therapeutic agent for the treatment of AUD. The Company’s AD04 also has the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity. The firm is also developing adenosine analogs for the treatment of pain and other disorders.
ADIAL PHARMACEUTICALS INC
1180 Seminole Trail, Suite 495
Charlottesville VIRGINIA 22901
P: 14344229800
CEO: William B. Stilley
Employees: 16
Website: https://www.adialpharma.com/
GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage...
We're starting off Thursday with a breakdown of all the biggest pre-market stock movers traders will want to keep an eye on this morning!
Adial Pharmaceuticals stock is up on Wednesday with heavy trading of ADIL shares alongside positive coverage of its AUD treatment.
Here you can normally see the latest stock twits on ADIL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: